source
- Sanofi’s new CEO vows deeper review of late-stage pipeline after series of trial failuresSanofi appointed Belén Garijo as chief executive in February with a clear mandate to tighten R&D governance and boost productivity. The board tasked her with bringing more rigor to the company’s st…
- J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutJohnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.Fierce Biotech · 8h ago↗ source